| Zugriffe | |
|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 173 |
| August 2024 | September 2024 | Oktober 2024 | November 2024 | Dezember 2024 | Januar 2025 | Februar 2025 | |
|---|---|---|---|---|---|---|---|
| Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 9 | 5 | 2 | 4 | 2 | 11 | 0 |
| Zugriffe | |
|---|---|
| 2021_Frost_etal.pdf | 233 |
